FDA to Review Topical PDE4-Inhibitor Roflumilast for Psoriasis FDA to Review Topical PDE4-Inhibitor Roflumilast for Psoriasis

In an open label phase 2b study of roflumilast, the treatment effect lasted for 52-64 weeks, according to the manufacturer.Medscape Medical News

Source: Medscape Dermatology Headlines - December 30, 2021 Category: Dermatology Tags: Dermatology News Source Type: news